Cost of Type 2 Diabetes Patients with Chronic Kidney Disease Based on Real-World Data: An Observational Population-Based Study in Spain

Ruth Usó-Talamantes, Silvia González- de-Julián, Javier Díaz-Carnicero, Inmaculada Saurí-Ferrer, José Luis Trillo-Mata, Marc Carrasco-Pérez, Jorge Navarro-Pérez, José Luis Górriz, David Vivas-Consuelo and Josep Redón
Additional contact information
Ruth Usó-Talamantes: Conselleria de Sanitat i Salut Pública, Generalitat Valenciana, 46010 Valencia, Spain
Silvia González- de-Julián: Research Unit for Health Economics and Management, Universitat Politècnica de València, 46022 Valencia, Spain
Javier Díaz-Carnicero: Research Unit for Health Economics and Management, Universitat Politècnica de València, 46022 Valencia, Spain
Inmaculada Saurí-Ferrer: INCLIVA Research Institute, 46010 Valencia, Spain
José Luis Trillo-Mata: Hospital Valencia Clínico–Malvarrosa, 46010 Valencia, Spain
Marc Carrasco-Pérez: Boehringer Ingelheim España S.A., 08174 Barcelona, Spain
Jorge Navarro-Pérez: INCLIVA Research Institute, 46010 Valencia, Spain
José Luis Górriz: INCLIVA Research Institute, 46010 Valencia, Spain
David Vivas-Consuelo: Research Unit for Health Economics and Management, Universitat Politècnica de València, 46022 Valencia, Spain
Josep Redón: INCLIVA Research Institute, 46010 Valencia, Spain

IJERPH, 2021, vol. 18, issue 18, 1-14

Abstract: This study analyzed the prevalence, costs and economic impact of chronic kidney disease CKD in patients with T2D in a Spanish Health District using real-world data. Observational cross-sectional study in adult patients with T2D was through data extracted from the information systems of the Valencia Clínico–La Malvarrosa Health District in the year 2015. Patients were stratified with the KDIGO classification for CKD. Additionally, patients were assigned to Clinical Risk Groups (CRGs) according to multimorbidity. Direct costs of primary and specialized care, and medication were estimated. The prevalence of T2D in the database population ( n = 28,345) was 10.8% (mean age (SD) = 67.8 years (13.9); 51.5% male). Up to 14.935 patients (52.6%) had data on kidney function. According to the KDIGO classification, 66.2% of the patients were at low risk of CKD, 20.6% at moderately increased risk, 7.9% at high risk, and 5.2% at very high risk. The average healthcare costs associated with these four risk groups were EUR 3437, EUR 4936, EUR 5899 and EUR 7389, respectively. The large number of T2D patients with CKD in the early stages of the disease generated a significant increase in direct healthcare costs. The economic impact could be mitigated by early and comprehensive therapeutic approaches.

Keywords: chronic kidney disease; type 2 diabetes; costs; healthcare resources; burden of care; KDIGO classification; Clinical Risk Groups (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/18/9853/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/18/9853/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:18:p:9853-:d:638791

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().